Valeant proposes to buy Allergan

  • April 22, 2014
  • Read the Perspective from Richard L. Lindstrom, MD

Valeant Pharmaceuticals has submitted a merger proposal to the board of directors of Allergan.

Under the proposal, each Allergan share would be exchanged for $48.30 in cash and 0.83 shares of Valeant common stock, according to a press release from Valeant. Allergan shareholders would be able to choose a mix of cash and shares and would own 43% of the combined company.

The proposal is based on Allergan’s unaffected stock price of $116.63 on April 10. The next day, Pershing Square Capital Management crossed the 5% ownership level in Allergan and commenced a rapid accumulation program, according to the release.
Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More »
More »
More »
  • Meeting News Coverage
  • OSN meeting
  • ASCRS 2014
  • Live onsite coverage from the Ophthalmology Innovation Summit and the American Society of Cataract and Refractive Surgeons annual meeting in Boston will begin on Thursday, April 24.
More »
  • Health Care Update
  • PQRS interim claims
  • 2013 PQRS interim claims feedback data now available for individual eligible professionals. Analysis by Catherine Brandon of Arnold & Porter LLP.
More »